Article
Oncology
Tao Dong, Jaimin R. Shah, Abraham T. Phung, Christopher Larson, Ana B. Sanchez, Omonigho Aisagbonhi, Sarah L. Blair, Bryan Oronsky, William C. Trogler, Tony Reid, Andrew C. Kummel
Summary: This study investigated the activity of an oncolytic adenovirus in tumors with low CAR expression. The results showed that liposome-encapsulated virus and viruses without liposome encapsulation achieved complete remission in 58% and 33% of the tumors, respectively. The study also found that an increased inflammatory infiltrate inside the tumor microenvironment is key to achieving effective therapeutic results in tumors independent of CAR expression. In addition, encapsulated adenovirus demonstrated an increased inflammatory infiltrate and reduced growth in distant tumors, while unencapsulated virus had limited inflammatory infiltrate and no effect on distant tumors.
Article
Oncology
Fuli Fan, Hyeon Joo Yoo, Sophia Stock, Lei Wang, Yibin Liu, Maria-Luisa Schubert, Sanmei Wang, Brigitte Neuber, Angela Hueckelhoven-Krauss, Ulrike Gern, Anita Schmitt, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt, Leopold Sellner
Summary: The use of ibrutinib has been shown to improve the viability and expansion of CART cells derived from CLL patients, enriching them with less-differentiated naive-like T cell subsets and reducing exhaustion marker expression. Additionally, ibrutinib enhances the cytokine release capacity of CLL patient-derived CART cells, suggesting it can improve the yield and function of these cell products.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Justyna Wos, Sylwia Chocholska, Wioleta Kowalska, Waldemar Tomczak, Agata Szymanska, Agnieszka Karczmarczyk, Agnieszka Szuster-Ciesielska, Agnieszka Wojciechowska, Agnieszka Bojarska-Junak
Summary: TEMs, characterized by the phenotype of CD14+CD16+Tie2+, have been identified as a new immunosuppressive force in tumors and are associated with unfavorable prognosis in CLL patients. Despite not being an independent predictor of survival, TEM can serve as an important complement to other prognostic indicators in CLL patients.
Article
Oncology
Iria Fernandez Botana, Giulia Pagano, Etienne Moussay, Jerome Paggetti
Summary: Chronic lymphocytic leukemia is the most common adult leukemia in the western world, and its interactions with the surrounding immune landscape are crucial for therapeutic interventions. Recent research has shown that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell mediated mechanism.
Article
Cell Biology
Yuanbin Cui, Tingjie Yuan, Ying Wang, Diwei Zheng, Le Qin, Shanglin Li, Zhiwu Jiang, Shouheng Lin, Wenjing Guo, Zhi Wang, Zhaoduan Liang, Yi Li, Yao Yao, Xingguo Liu, Qiannan Tang, Hai-Yan Tu, Xu-Chao Zhang, Zhaoyang Tang, Nathalie Wong, Zhenfeng Zhang, Dajiang Qin, Jean Paul Thiery, Kailin Xu, Peng Li
Summary: A switchable CAR vector called CFR64, designed with a CD64 extracellular domain, is shown to have better efficacy in treating solid tumors compared to conventional CAR T cells. CFR64 T cells exhibit more robust cytotoxicity, better long-term activity, and resistance to T cell exhaustion. The use of CFR64 with trastuzumab also results in a more stable immunological synapse with lower downstream signaling induction compared to anti-HER2 CAR T cells.
Review
Biochemistry & Molecular Biology
Veronika Mancikova, Michal Smida
Summary: CAR T-cell therapy has shown remarkable remissions in difficult-to-treat patients with B-cell malignancies, but the efficacy in chronic lymphocytic leukemia patients is the lowest among B-cell tumors, requiring further investigation into treatment mechanisms and failure reasons.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Elisavet Vlachonikola, Kostas Stamatopoulos, Anastasia Chatzidimitriou
Summary: The treatment of chronic lymphocytic leukemia (CLL) is continuously evolving, with immunotherapy emerging as a therapeutic option to boost immune responses against tumors. However, not all patients benefit from this approach, partly due to dysfunctional T cells in CLL. The tumor microenvironment (TME) is also crucial in impacting immune responses and tumor growth, highlighting the importance of understanding T cell defects and finding ways to overcome them for effective immunotherapy in CLL.
Article
Biotechnology & Applied Microbiology
Lin Ang, Jiang Li, Hui Dong, Chunhong Wang, Jin Huang, Mingcong Li, Min Zhao, Changqing Su, Qiang Wu
Summary: This study constructed a new therapeutic strategy based on oncolytic adenovirus, which not only exerted oncolytic effect on breast cancer cells, but also enhanced the chemotactic effect of immune cells, resulting in a synergistic effect on tumor inhibition and immune response.
BIOENGINEERING-BASEL
(2022)
Article
Oncology
Fang Huang, Zhichao Li, Wenhao Zhang, Jiaqi Li, Siguo Hao
Summary: Cell-released nanovesicles, or exosomes, derived from leukemia cells can induce anti-leukemia immunity. However, the presence of immunosuppressive PD-L1 proteins in these exosomes reduces the potency of exosome-based vaccines. In this study, researchers successfully downregulated PD-L1 expression in leukemia cells and exosomes using lentivirus-mediated PD-L1 shRNA. The resulting exosomes, termed LEXPD-L1si, showed enhanced immune effects compared to non-modified exosomes, including increased DC maturation, T cell activation, T cell proliferation, and cytokine release. Vaccination with LEXPD-L1si effectively inhibited tumor growth and prolonged survival in mice. This study highlights the potential application of optimizing exosome-based vaccines for leukemia immunotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, Alaa Fadhil Alwan, Gianluca Gaidano
Summary: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Chemoimmunotherapy (CIT) was the commonest option for CLL treatment, but resistance to CIT has led to the use of targeted pathway inhibitors such as BTK and BCL2 inhibitors. However, acquired genetic lesions can cause resistance to these inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Zong-Han Wang, Wei Li, Hao Dong, Fujun Han
Summary: Chronic lymphocytic leukemia (CLL) is a common hematological disease with a high incidence in western countries. Conventional chemotherapy and targeted therapeutic drugs have limitations in high-risk patients. Immunotherapy, particularly using natural killer (NK) cells, has shown potential for improved prognosis. NK cells enhance immune response through various mechanisms, including antibody-dependent cytotoxicity (ADCC), allogeneic NK cell therapy, and CAR-NK cell therapy. This article reviews the characteristics of NK cells, their receptors, and the advantages and disadvantages of NK cell-based immunotherapies for CLL.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Francesca Perutelli, Rebecca Jones, Valentina Griggio, Candida Vitale, Marta Coscia
Summary: Immune-based therapeutic strategies have revolutionized the treatment of hematological disorders by enhancing the immune response against tumor cells. However, individual use of immunotherapy has not shown optimal results in terms of disease control due to CLL-related immune dysfunctions. The understanding of the interactions between immune cells and tumor cells has led to the development of novel combination approaches that hold promise for future treatment of CLL.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yasuhiro Shirakawa, Hiroshi Tazawa, Shunsuke Tanabe, Nobuhiko Kanaya, Kazuhiro Noma, Takeshi Koujima, Hajime Kashima, Takuya Kato, Shinji Kuroda, Satoru Kikuchi, Shunsuke Kagawa, Kuniaki Katsui, Susumu Kanazawa, Yasuo Urata, Toshiyoshi Fujiwara
Summary: Combining OBP-301 with radiotherapy in oesophageal cancer patients unfit for standard treatments resulted in a high rate of local complete response and objective response, indicating the feasibility and effectiveness of this treatment approach for patients unable to undergo surgery or chemotherapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Dafne C. A. Quixabeira, Victor Cervera-Carrascon, Joao M. Santos, James H. A. Clubb, Tatiana V. Kudling, Saru Basnet, Camilla Heinio, Susanna Gronberg-Vaha-Koskela, Marjukka Anttila, Riikka Havunen, Anna Kanerva, Akseli Hemminki
Summary: This study demonstrates that the combination treatment of local injection of adenovirus coding for TNFa and IL-2 and systemic aPD-1 therapy can effectively control both injected and non-injected tumors in animal models. The treatment reshapes the tumor microenvironment and enhances the systemic antitumor response.
Article
Immunology
Annika Nelde, Yacine Maringer, Tatjana Bilich, Helmut R. Salih, Malte Roerden, Jonas S. Heitmann, Ana Marcu, Jens Bauer, Marian C. Neidert, Claudio Denzlinger, Gerald Illerhaus, Walter Erich Aulitzky, Hans-Georg Rammensee, Juliane S. Walz
Summary: The study developed an immunopeptidome-guided workflow for designing tumor-associated off-the-shelf peptide warehouses for broadly applicable personalized therapeutics, which can be easily transferred to other tumor entities and serve as the foundation for broad personalized T cell-based immunotherapy approaches.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
E. Moreno-Cortes, J. V. Forero-Forero, P. A. Lengerke-Diaz, J. E. Castro
Summary: The rapid growth of CAR T-cell therapy in clinical trials, particularly in the field of hematologic malignancies, is evident. Apart from China and the USA, other countries are also starting to participate in research in this area, with the expectation of more CAR T-cell therapy clinical trials in the future.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Hematology
Megan Melody, Sangeetha Gandhi, Zaid Abdel Rahman, Paula Lengerke-Diaz, Nicole Gannon, Allison Rosenthal, Tuan Truong, Mattia Novo, Eva Brandes, Gina Lange, Breana Estby, Patrick Johnston, Steve Ansell, N. Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Ernesto Ayala, Han W. Tun, Hemant S. Murthy, Vivek Roy, James Foran, Januario Castro, Yi Lin, Mohamed A. Kharfan-Dabaja
Summary: This retrospective analysis of 81 patients treated with axi-cel showed that 22.8% had hypoalbuminemia. Results indicated that axi-cel therapy appeared to overcome the adverse prognostic impact of hypoalbuminemia on overall survival and progression-free survival in these patients. Further large multicenter clinical studies are needed to validate these findings.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Meeting Abstract
Oncology
Jose Vicente Forero-Forero, Juan Esteban Garcia-Robledo, Daniela A. Castro-Martinez, Eider Felipe Moreno, Paula Andrea Lengerke Diaz, Natalie Booth, Januario E. Castro
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Megan Melody, Sangeetha Gandhi, Hollie Saunders, Zaid Abdel-Rahman, Jacquelyn Hastings, Paula Lengerke Diaz, Nicole Gannon, Tuan Truong, Matthew Hathcock, Arushi Khurana, Patrick Johnston, Stephen Ansell, Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Yucai Wang, Allison Rosenthal, James Foran, Ernesto Ayala, Hemant S. Murthy, Vivek Roy, Januario E. Castro, Yi Lin, Mohamed A. Kharfan-Dabaja
Summary: Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma, but comes with unique toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. A retrospective analysis of patients treated with axicabtagene ciloleucel (axi-cel) showed a low risk of thrombosis in axi-cel recipients.
LEUKEMIA & LYMPHOMA
(2022)
Article
Biochemistry & Molecular Biology
Maria Zingariello, Paola Verachi, Francesca Gobbo, Fabrizio Martelli, Mario Falchi, Maria Mazzarini, Mauro Valeri, Giuseppe Sarli, Christian Marinaccio, Johanna Melo-Cardenas, John D. Crispino, Anna Rita Migliaccio
Summary: Inflammatory cytokine levels in bone marrow, rather than blood levels, are closely related to myelofibrosis in Gata1(low) mice, possibly through reshaping the HSC niche.
Article
Cell Biology
Deepak Kumar, Manoj K. Kashyap, Zhe Yu, Ide Spaanderman, Reymundo Villa, Thomas J. Kipps, James J. La Clair, Michael D. Burkart, Januario E. Castro
Summary: Alterations in RNA splicing are associated with malignancies. This study found that the RNA splicing modulators FD-895 and pladienolide B can induce higher apoptosis levels and inhibit solid tumor growth by modulating the Wnt signaling pathway and mRNA splicing.
Letter
Oncology
Jacqui-Lyn Saw, M. Hasib Sidiqi, Michael Ruff, Sara Hocker, Hassan Alkhateeb, Stephen M. Ansell, N. Nora Bennani, David Dingli, Suzanne R. Hayman, Patrick B. Johnston, Prashant Kapoor, Saad J. Kenderian, Taxiarchis V. Kourelis, Shaji K. Kumar, Jonas Paludo, Mithun V. Shah, Mustaqeem A. Siddiqui, Rahma Warsame, Allison Rosenthal, Marie Grill, Januario E. Castro, Jason Siegel, Zaid H. Abdel Rahman, Mohamed A. Kharfan-Dabaja, Elson So, Yi Lin
BLOOD CANCER JOURNAL
(2022)
Letter
Hematology
Evandro D. Bezerra, Madiha Iqbal, Javier Munoz, Arushi Khurana, Yucai Wang, Matthew J. Maurer, Radhika Bansal, Matthew A. Hathcock, Nora Bennani, Hemant S. Murthy, Allison C. Rosenthal, Jonas Paludo, Jose C. Villasboas, Patrick B. Johnston, Thomas M. Habermann, Stephen M. Ansell, Januario E. Castro, Thomas E. Witzig, Mohamed A. Kharfan-Dabaja, Grzegorz S. Nowakowski, Yi Lin
Review
Oncology
Ginna Granroth, Allison Rosenthal, Maggie McCallen, Christopher Coughlin, Hollie Benson, Jeanne Palmer, Januario E. Castro, Javier Munoz
Summary: This paper aims to describe the comprehensive supportive care for patients with relapsed or refractory lymphoma undergoing cellular therapy, focusing on the perspective of advanced practice providers (APPs). Recent findings indicate that CAR-T cell therapy is increasingly used for treating relapsed or refractory B-cell hematologic malignancies. APPs play a pivotal role in supporting these patients throughout their treatment.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Hematology
Johanna Melo-Cardenas, John D. Crispino
Article
Oncology
Julia E. Wiedmeier-Nutor, Madiha Iqbal, Allison C. Rosenthal, Evandro D. Bezerra, Juan Esteban Garcia-Robledo, Radhika Bansal, Patrick B. Johnston, Matthew Hathcock, Jeremy T. Larsen, P. Leif Bergsagel, Yucai Wang, Craig B. Reeder, Jose F. Leis, Rafael Fonseca, Jeanne M. Palmer, Brianna J. Gysbers, Raphael Mwangi, Rahma M. Warsame, Taxiarchis Kourelis, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Shaji K. Kumar, Urshila Durani, Jose C. Villasboas, Jonas Paludo, N. Nora Bennani, Grzegorz Nowakowski, Stephen M. Ansell, Januario E. Castro, Mohamed A. Kharfan-Dabaja, Yi Lin, Paschali Veridis, Hemant S. Murthy, Javier Munoz
Summary: This study evaluated the levels of SARS-CoV-2 spike-binding IgG antibodies in non-Hodgkin lymphoma and multiple myeloma CAR T therapy recipients after COVID-19 vaccination. It found that only a minority of these patients were able to mount a clinically relevant antibody response (> 250 IU/mL).
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Hematology
Juan Esteban Garcia-Robledo, Cristina Valencia-Sanchez, Molly G. Knox, Brent P. Goodman, Allison C. Rosenthal, Bhavesh Patel, Januario E. Castro
Summary: Bedside sonographic measurement of optic nerve sheath diameter is helpful in diagnosing elevated intracranial pressure, and proved valuable in a case of immune effector cell-associated neurotoxicity syndrome. The patient showed wide optic nerve sheath diameters and bulging optic discs bilaterally. Prompt treatment resulted in a successful recovery with no long-term neurological deficits.
HEMATOLOGY REPORTS
(2023)
Article
Hematology
Johanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, Sandeep Gurbuxani, Anitria Cotton, Guolian Kang, Jeffrey Gossett, Christian Marinaccio, Rona Weinberg, Ronald Hoffman, Anna Rita Migliaccio, Yan Zheng, Marta Derecka, Ciro R. Rinaldi, John D. Crispino
Summary: This study analyzed MF mouse models and samples from MF patients, and found that high levels of IL-13 are associated with MF progression and fibrosis. Inhibition of the IL-13/IL-4 signaling pathway may serve as a novel therapeutic target for treating MF.
Article
Hematology
Emin Kansu, David Ward, Amber P. Sanchez, Robyn Cunard, Mutlu Hayran, Beril Huseyin, Majella Vaughan, Grace Ku, Peter Curtin, Carolyn Mulroney, Caitlin Costello, Januario E. Castro, Matthew Wieduwilt, Sue Corringham, Anita Ihasz-Davis, Connie Nelson, Edward D. Ball
Summary: This retrospective study evaluated the effectiveness of extracorporeal photopheresis (ECP) in treating chronic graft versus host disease (GVHD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. The study found that ECP showed the best responses in skin, mouth mucosa, eyes, and liver. The overall response rate was 81.2%, with a higher response rate observed in female patients.
Meeting Abstract
Biophysics
Megan Melody, Sangeetha Gandhi, Zaid Abdel Rahman, Paula Lengerke Diaz, Nicole Gannon, Allison Rosenthal, Taun Truong, Mattia Novo, Eva Brandes, Gina Lange, Breana Etsby, Patrick Johnston, Steve Ansell, N. Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Ernesto Ayala, Han W. Tun, Hemant Murthy, Vivek Roy, James Foran, Januario Castro, Yi Lin, Mohamed Kharfan-Dabaja
BONE MARROW TRANSPLANTATION
(2020)